These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 35210989)
61. Progress of RAGE Molecular Imaging in Alzheimer's Disease. Kong Y; Liu C; Zhou Y; Qi J; Zhang C; Sun B; Wang J; Guan Y Front Aging Neurosci; 2020; 12():227. PubMed ID: 32848706 [TBL] [Abstract][Full Text] [Related]
62. In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer. Fodero-Tavoletti MT; Brockschnieder D; Villemagne VL; Martin L; Connor AR; Thiele A; Berndt M; McLean CA; Krause S; Rowe CC; Masters CL; Dinkelborg L; Dyrks T; Cappai R Nucl Med Biol; 2012 Oct; 39(7):1042-8. PubMed ID: 22503458 [TBL] [Abstract][Full Text] [Related]
63. Preclinical Evaluation of [(18)F]THK-5105 Enantiomers: Effects of Chirality on Its Effectiveness as a Tau Imaging Radiotracer. Tago T; Furumoto S; Okamura N; Harada R; Adachi H; Ishikawa Y; Yanai K; Iwata R; Kudo Y Mol Imaging Biol; 2016 Apr; 18(2):258-66. PubMed ID: 26194011 [TBL] [Abstract][Full Text] [Related]
64. Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer's Disease. Rahman MS; Uddin MS; Rahman MA; Samsuzzaman M; Behl T; Hafeez A; Perveen A; Barreto GE; Ashraf GM Curr Pharm Des; 2021; 27(38):4017-4029. PubMed ID: 34126892 [TBL] [Abstract][Full Text] [Related]
65. Alternative approaches for PET radiotracer development in Alzheimer's disease: imaging beyond plaque. Holland JP; Liang SH; Rotstein BH; Collier TL; Stephenson NA; Greguric I; Vasdev N J Labelled Comp Radiopharm; 2014 Apr; 57(4):323-31. PubMed ID: 24327420 [TBL] [Abstract][Full Text] [Related]
66. Comparative binding properties of the tau PET tracers THK5117, THK5351, PBB3, and T807 in postmortem Alzheimer brains. Lemoine L; Gillberg PG; Svedberg M; Stepanov V; Jia Z; Huang J; Nag S; Tian H; Ghetti B; Okamura N; Higuchi M; Halldin C; Nordberg A Alzheimers Res Ther; 2017 Dec; 9(1):96. PubMed ID: 29229003 [TBL] [Abstract][Full Text] [Related]
67. Tau Imaging in Neurodegenerative Diseases Using Positron Emission Tomography. Wang YT; Edison P Curr Neurol Neurosci Rep; 2019 Jun; 19(7):45. PubMed ID: 31172290 [TBL] [Abstract][Full Text] [Related]
68. Structure-Activity Relationship of 2-Arylquinolines as PET Imaging Tracers for Tau Pathology in Alzheimer Disease. Tago T; Furumoto S; Okamura N; Harada R; Adachi H; Ishikawa Y; Yanai K; Iwata R; Kudo Y J Nucl Med; 2016 Apr; 57(4):608-14. PubMed ID: 26697966 [TBL] [Abstract][Full Text] [Related]
69. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. Whitwell JL; Ahlskog JE; Tosakulwong N; Senjem ML; Spychalla AJ; Petersen RC; Jack CR; Lowe VJ; Josephs KA Parkinsonism Relat Disord; 2018 Mar; 48():3-9. PubMed ID: 29254665 [TBL] [Abstract][Full Text] [Related]
71. Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. Chiotis K; Saint-Aubert L; Savitcheva I; Jelic V; Andersen P; Jonasson M; Eriksson J; Lubberink M; Almkvist O; Wall A; Antoni G; Nordberg A Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1686-99. PubMed ID: 26996778 [TBL] [Abstract][Full Text] [Related]
72. Relationship between the temporal course of astrogliosis and symptom improvement in cerebral infarction: report of a case monitored using Ishibashi K; Miura Y; Hirata K; Toyohara J; Ishii K BMC Med Imaging; 2020 Jul; 20(1):81. PubMed ID: 32664871 [TBL] [Abstract][Full Text] [Related]
73. Park S; Oh M; Kim JS; Lee JH; Yoon YW; Roh JH Brain Sci; 2021 Apr; 11(4):. PubMed ID: 33917613 [TBL] [Abstract][Full Text] [Related]